Press Releases

Date	Title
August 3, 2022	Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
July 27, 2022	Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
June 29, 2022	Corcept Therapeutics Initiates ROSELLA – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer
June 6, 2022	Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
May 5, 2022	Corcept Therapeutics Announces First Quarter Financial Results And Provides Corporate Update
April 28, 2022	Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
April 7, 2022	Corcept Therapeutics Announces Appointment of Three Senior Leaders
April 4, 2022	Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant in Patients with Antipsychotic-Induced Weight Gain
March 30, 2022	Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer
March 1, 2022	Corcept Therapeutics to Host Ovarian Cancer Program Update on Thursday, March 31, 2022